Teva launches Lialda generic
Teva has introduced its Lialda generic (mesalamine delayed-release tablets). The drug is indicated to treat mild-to-moderate ulcerative colitis.
“The launch of mesalamine is a significant addition to Teva’s generic portfolio,” Teva executive vice president and head of North American Commercial Brendan O’Grady said. “With more than a million people in the U.S. estimated to suffer from inflammatory bowel diseases, including ulcerative colitis, this is an important and more affordable generic treatment option for our customers.”
Teva’s Lialda generic will be available in 1.2-g dosage strength. The product’s market size was roughly $1.11 billion for the 12 months ended January 2018, according to IQVIA data.
Lupin intros generic Lodosyn
Lupin has launched its generic of Lodosyn (carbidopa) tablets. The company had previously received approval from the Food and Drug Administration for the generic, which is indicated to treat symptoms associated with Parkinson’s disease alongside carbidopa-levodopa or levodopa.
Lupin’s generic Lodosyn will be available in 25-mg dosage strength. The product has a market size of roughly $17.4 million for the 12 months ended January 2018, according to IQVIA data.
Mayne Pharma’s generic Quartette launches
Mayne Pharma has introduced its generic Quartette. The contraceptive product is a combination of levonorgestrel and ethinyl estradiol tablets, 0.15mg/0.02mg; 0.15mg/0.025mg; 0.15mg/0.03mg and ethinyl estradiol tablets, 0.01mg, and adds to the company’s already existing 22 marketed women’s health products.
“Mayne Pharma is the second largest supplier of oral contraceptive products in the United States and continues to invest in growing its pipeline of women’s health products with high value, complex formulations such as generic NuvaRing, an intravaginal hormonal contraceptive delivery device which recently was accepted for filing by the FDA,” Mayne Pharma CEO Scott Richards said
The Adelaide, Australia-based company’s generic Quartette launches into a market that had estimated sales of roughly $10 million for the 12 months ended January 2018.